Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2023-02-03 10:44 am Unchanged | 13G | Gene Biotherapeutics Inc. CRXM | Jemapete Christopher J | 4,000,000 6.200% | 0 (Unchanged) | View |
| 2022-01-04 9:23 pm Sale | 13G | Gene Biotherapeutics Inc. CRXM | SABBY MANAGEMENT LLC | 0 0.000% | -1,435,917 (Position Closed) | View |
| 2021-04-28 4:20 pm Unchanged | 13G | Gene Biotherapeutics Inc. CRXM | Jemapete Christopher J | 4,000,000 8.100% | 0 (Unchanged) | View |
| 2021-03-18 2:05 pm Purchase | 13D | Gene Biotherapeutics Inc. CRXM | Jemapete Christopher J | 4,000,000 27.600% | 500,000 (+14.29%) | View |
| 2021-03-01 4:48 pm Purchase | 13D | Gene Biotherapeutics Inc. CRXM | Jemapete Christopher J | 3,500,000 24.200% | 3,500,000 (New Position) | View |
| 2020-12-22 3:23 pm Purchase | 13G | Gene Biotherapeutics Inc. CRXM | Coluccio Christian F | 725,000 5.000% | 725,000 (New Position) | View |
| 2020-06-01 5:27 pm Purchase | 13D | Gene Biotherapeutics Inc. CRXM | Nostrum Pharmaceuticals LLC | 150,442,478 91.200% | 150,442,478 (New Position) | View |